Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

<p>Abstract</p> <p>Background</p> <p>Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression (TTP) may be more s...

Full description

Bibliographic Details
Main Authors: Goffin John R, Pond Greg R
Format: Article
Language:English
Published: BMC 2011-12-01
Series:BMC Medical Research Methodology
Subjects:
early progressive disease
phase II trial
response rate
simulation
stopping rules
time to progression
Online Access:http://www.biomedcentral.com/1471-2288/11/164

Internet

http://www.biomedcentral.com/1471-2288/11/164

Similar Items